{"filing":{"accession_number":"0001104659-26-076822","cik":"0001671502","ticker":"QNRX","company_name":"Quoin Pharmaceuticals, Ltd.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"tm2618505d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926076822/tm2618505d1_8k.htm"},"events":[{"id":13168,"run_id":11688,"accession_number":"0001104659-26-076822","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Quoin announced FDA conditional approval of the brand name QYLEKI™ for QRX003, its investigational treatment for Netherton Syndrome, representing a material regulatory milestone in the drug development pathway. The company expects to initiate a Phase 3 pivotal study in H2 2026 and anticipates filing an NDA in 2027, advancing the lead candidate toward potential commercialization.","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10237,"accession_number":"0001104659-26-076822","item_number":"7.01","item_title":"Regulation","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA conditional approval of the brand name QYLEKI™ for QRX003, Quoin's investigational product for Netherton Syndrome. This is a regulatory milestone in the drug development process—not a financial event, M\u0026A activity, or governance matter. While the company is a late-stage clinical pharmaceutical firm, the conditional brand name approval itself is an operational/regulatory achievement that advances the product toward commercialization. The event is material because it represents progress toward potential market approval of the company's lead candidate and would affect investor assessment of development trajectory, though it is not as material as actual FDA approval or clinical trial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:16:50.057411+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10239,"accession_number":"0001104659-26-076822","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA conditional approval of the brand name QYLEKI for QRX003, Quoin's investigational treatment for Netherton Syndrome. This is a regulatory milestone in the drug development pathway—the company is progressing toward potential commercialization with a Phase 3 study expected in H2 2026 and NDA filing anticipated in 2027. While not a completed approval or a traditional operational event, the brand name approval represents meaningful progress on a late-stage clinical asset and would be material to investors assessing the company's regulatory trajectory and commercialization readiness for its lead product.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:16:50.057411+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10237,"accession_number":"0001104659-26-076822","item_number":"7.01","item_title":"Regulation","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA conditional approval of the brand name QYLEKI™ for QRX003, Quoin's investigational product for Netherton Syndrome. This is a regulatory milestone in the drug development process—not a financial event, M\u0026A activity, or governance matter. While the company is a late-stage clinical pharmaceutical firm, the conditional brand name approval itself is an operational/regulatory achievement that advances the product toward commercialization. The event is material because it represents progress toward potential market approval of the company's lead candidate and would affect investor assessment of development trajectory, though it is not as material as actual FDA approval or clinical trial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:16:50.057411+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-06-23"},{"id":10239,"accession_number":"0001104659-26-076822","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA conditional approval of the brand name QYLEKI for QRX003, Quoin's investigational treatment for Netherton Syndrome. This is a regulatory milestone in the drug development pathway—the company is progressing toward potential commercialization with a Phase 3 study expected in H2 2026 and NDA filing anticipated in 2027. While not a completed approval or a traditional operational event, the brand name approval represents meaningful progress on a late-stage clinical asset and would be material to investors assessing the company's regulatory trajectory and commercialization readiness for its lead product.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:16:50.057411+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-06-23"}]}